Fulgent Genetics, Inc. (FLGT) Guidance & Earnings Results

On 2026-07-30 Fulgent Genetics, Inc. lowered guidance: "FY26 revenue revised to $330-340M from prior range; FY26 non-GAAP loss $63-67M; FY26 non-GAAP loss per share $2.22-2.35; FY26 cash ~$610M including $63.9M YTD repurchases; capex $12M; therapeutic development spend…" — from its own filing, as read by EquiReason.

Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason

FLGTFulgent Genetics, Inc.Follow FLGT — free

Diagnostics & Research · Healthcare

—

Price chart with a free account

Market cap: 553.1M
P/E TTM: —
Dividend yield: —
52-week: —
Next earnings: 5 Nov, in 12 days

What management guided

each earnings 8-K · figures checked against the filing text

Release	Direction	What they said
30 Jul 26	Lowered	FY26 revenue revised to $330-340M from prior range; FY26 non-GAAP loss $63-67M; FY26 non-GAAP loss per share $2.22-2.35; FY26 cash ~$610M including $63.9M YTD repurchases; capex $12M; therapeutic development spend $26M · full year
1 May 26	Reaffirmed	FY2026 revenue ~$350M; non-GAAP loss ~$46M; non-GAAP loss per share ~$(1.59) · full year
27 Feb 26	Raised	FY2026 revenue ~$350M vs FY2025 actual $322.7M, +8.5%
7 Nov 25	Raised	Revenue guidance raised to $325M; non-GAAP EPS guidance raised to $0.30 · full year
1 Aug 25	Raised	FY2025 core revenue raised to ~$320M; GAAP loss ~($2.10)/share; non-GAAP loss ~($0.35)/share; cash ~$770M · full year

Fulgent Genetics, Inc. — questions

What guidance did Fulgent Genetics, Inc. give?: On 2026-07-30: "FY26 revenue revised to $330-340M from prior range; FY26 non-GAAP loss $63-67M; FY26 non-GAAP loss per share $2.22-2.35; FY26 cash ~$610M including $63.9M YTD repurchases; capex $12M; therapeutic development spend $26M"
When does Fulgent Genetics, Inc. report earnings?: Fulgent Genetics, Inc.'s next earnings report is expected on 2026-11-05.

Every figure on this page comes from Fulgent Genetics, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.

How these figures are read: methodology · EquiReason.

Important information. Figures on this page are taken from filings submitted to the U.S. Securities and Exchange Commission (SEC) and processed automatically by EquiReason. They may contain errors, omissions or delays, and EquiReason makes no representation or warranty as to their accuracy, completeness or timeliness. Always verify figures against the original filing on SEC EDGAR before relying on them.

This page is provided for general information and educational purposes only. It does not constitute investment, financial, legal or tax advice, and it is not a recommendation or an offer to buy, sell or hold any security. It does not take into account your objectives, financial situation or needs. Past performance does not guarantee future results; any reliance on this information is at your own risk. See our Disclaimer and Risk Disclosure.